View ValuationConvatec Group 将来の成長Future 基準チェック /36Convatec Group利益と収益がそれぞれ年間19.8%と6.1%増加すると予測されています。EPS は年間 増加すると予想されています。自己資本利益率は 3 年後に24.4% 19.9%なると予測されています。主要情報19.8%収益成長率19.92%EPS成長率Medical Equipment 収益成長16.1%収益成長率6.1%将来の株主資本利益率24.42%アナリストカバレッジGood最終更新日21 May 2026今後の成長に関する最新情報お知らせ • Nov 13Convatec Group plc Maintains Revenue Guidance for the Year 2025ConvaTec Group PLC maintained revenue guidance for the year 2025. FY25 Group organic revenue growth excluding InnovaMatrix 6.0-6.5% (previously 5.5-7.0%). Medium-term targets: 5-7% organic revenue.お知らせ • Jul 31+ 1 more updateConvaTec Group PLC Provides Revenue Guidance for the Year 2025ConvaTec Group PLC provided revenue guidance for the year 2025. Group organic revenue growth excluding InnovaMatrix of 5.5%-7.0% (unchanged) driven by broadening product portfolio and focused commercial execution. InnovaMatrix® revenue of at least $75 million (unchanged).お知らせ • May 17ConvaTec Group PLC Provides Revenue Guidance for the Full Year 2024ConvaTec Group PLC provided revenue guidance for the full year 2024. Given the strong start so far this year, the company expects more balanced growth between first half and the second half of the year, and the company is on track to deliver its full year guidance of 5% to 7% organic revenue growth.お知らせ • Nov 14ConvaTec Group PLC Revises Earnings Guidance for the Year 2023ConvaTec Group PLC revised earnings guidance for the year 2023. For the year, the company now expect organic revenue growth for 2023 to be between 6.75% and 7.5% (previously 6.0%-7.5%).お知らせ • May 19ConvaTec Group PLC Provides Revenue Guidance for the Year 2023ConvaTec Group PLC provided revenue guidance for the year 2023. For the year, the company now expects organic revenue growth to be between 5.0% and 6.5% (previously 4.5%-6.0%).すべての更新を表示Recent updatesお知らせ • May 06Convatec Showcases and Launches Advanced Wound Care Products and TechnologiesConvatec, a medical products and technology company focused on chronic condition management, took to the stage to showcase the breadth, depth and momentum behind its Advanced Wound Care innovation pipeline at the European Wound Management Association (EWMA) 2026 conference in Bremen, Germany, from 6–8 May 2026. Convatec’s Advanced Wound Care innovation is supported by compelling new data from randomised controlled trials (RCTs) and real-world studies, with 13 abstracts accepted for publication and presentation at EWMA evaluating outcomes in hard-to-heal wounds across foam, multimodal, nitric oxide-generating dressings, antimicrobial technology and Wound Hygiene. Convatec has launched or secured approvals for five new wound care products since 2022, including: ConvaFoam™: Best-in-class multi-layer foam dressing designed to be repositionable on application to avoid wasted dressing changes. ConvaFoam™ is the only foam dressing that combines three technologies – Aquacel® Hydrofiber®, superabsorber fibers and ConvaTac™ silicone – to deliver superior exudate management with skin friendly adhesion for longer lasting wear time. ConvaNiox™: A solution, shaping a new category in the management of hard-to-heal wounds by combining an advanced dressing technology with a powerful antimicrobial and antibiofilm agent, nitric oxide. ConvaNiox™’s multimodal technology, MultiFusion™, supports the healing of 60% more diabetic foot ulcers (DFUs), with 3x faster wound area reduction compared to standard-of-care dressings. Aquacel™ ConvaFiber™: Next-generation, soft, sterile and conformable primary dressing with advanced Hydrofiber® technology resulting in 45% more absorbency (vs Aquacel® Extra™), designed to manage a broad range of acute and chronic wounds. ConvaMatrix™: Recently approved innovative, single use wound matrix - a unique porcine placental-derived technology designed to support the body's natural healing response in DFUs and venous leg ulcers (VLUs). It combines the structural benefits of the placenta with the reproducibility and safety profile of a medical device. ConvaVAC™: First and only Negative Pressure Wound Therapy (NPWT) system partnered with Aquacel® Hydrofiber® technology utilising a bacterial sequestration and autolytic debridement wound contact layer to control the bioburden whilst delivering NPWT to promote wound healing. This year’s EWMA programme also marks 30 years of Hydrofiber® technology, Convatec’s proprietary wound care platform that underpins the next generation of wound care innovation to help manage the burden of wound care. Almost 1,500,000,000 Aquacel® dressings have been sold worldwide leveraging the technology over the last three decades. As part of the scientific programme at EWMA 2026, Convatec will host a series of symposia to explore emerging evidence from across its Advanced Wound Care portfolio and discuss what it means for real-world clinical practice, including: 6 May 2026 from 16:00 – 17:00: Introducing ConvaNiox™: multimodal, nitric oxide-generating dressing. The session, chaired by Professor José Luis Lázaro-Martínez, University of Madrid, will explore emerging laboratory and clinical evidence, highlighting ConvaNiox™’s multimodal approach to support healing in diabetic foot ulcers. 7 May 2026 from 16:16 – 17:15: A year of healing with ConvaFoam™: Advancing wound care with a next-generation foam dressing. The session will focus on the published clinical data exploring ConvaFoam™’s mode of action in pressure injury prevention, including insights on complex cases from guest speaker Dr Przemyslaw Lipinski, ARGO Medical Centre. Title Lead presenter Session information (CEST) Aquacel® Ag+ Extra™ Enhanced silver dressing versus dialkylcarbamoyl chloride-coated dressing in venous leg ulcers: a blinded re-assessment of randomized controlled trial findings Rebecca Rodger Wednesday 6 May 17:35 - 17:43 Room 4B Enhanced silver dressing improves slough and debridement in venous leg ulcers: post hoc analysis of a randomised controlled trial Rebecca Rodger Thursday 07 May 13:33 – 13:37 E-Poster Screen 4 ConvaNiox™ Assessing the speed of antimicrobial activity of a nitric oxide-generating dressing against antibiotic-resistant wound pathogens Tilly Coleborn Wednesday 6 May 12:17 - 12:21 E-Poster Screen 2 Assessing the sustained antimicrobial activity of a nitric oxide-generating dressing using antibiotic-resistant wound pathogens in a repeated inoculation model Tilly Coleborn Wednesday 6 May 12:21 - 12:25 E-Poster Screen 2 A multimodal dressing NO-generating: An Option for Both Acute and Chronic Wounds Dr. Francesca Pasquali Wednesday 6 May 12:29 - 12:33 CEST E-Poster Screen 2 Effectiveness of a nitric oxide-generating dressing in patients with diabetic foot ulcers: preliminary data from a case series study Dr. Marco Meloni Thursday 7 May 13:20 - 13:25 E-Poster Screen 3 To assess real-world characteristics and short-term outcomes of diabetic foot ulcers (DFUs) managed with a multi-modal nitric oxide-generating medical device using a structured clinical follow-up case report form Natalia Maella-Rius Thursday 7 May 13:30 - 13:35 E-Poster Screen 3 ConvaFoam™ Performance and user satisfaction with a superabsorbent dressing: results from an international survey Janet MacKenzie Thursday 7 May 12:54 – 12:57 E-Poster Screen 2 Early outcomes of implementing a new multilayer foam dressing in an acute setting: Assessing clinical and financial impact through value-based procurement Rebecca Rodger Thursday 7 May 16:10 - 16:15 E-Poster Screen 4 ConvaMatrix™ The clinical performance of decellularized porcine placental extracellular matrix (PPECM) in hard-to-heal wounds at a single-center: a retrospective study Helen Hahn Wednesday 6 May 00:00 - 00:00 E-poster browsing stations for display Real-world use of porcine placental extracellular matrix (PPECM) in hard-to-heal wounds: retrospective, multicenter analysis Helen Hahn Wednesday 6 May 00:00 - 00:00 E-poster browsing stations for display Real world data Hospital-to-home transition and care coordination in wound management: cost-effectiveness evaluation in a Brazilian specialized service Michele Rocha Thursday 7 May 10:36 - 10:39 E-Poster Screen 4 Therapeutic success indicators in hard-to-heal wounds: effectiveness of a specialized ambulatory care model Michele Rocha Thursday 7 May 16:30 - 16:35 E-Poster Screen 4.お知らせ • Apr 13Convatec Group Plc Announces Professor Constantin Coussios OBE Steps Down as Non-Executive Director, Effective April 30, 2026Convatec Group Plc announces that Professor Constantin Coussios OBE will be stepping down as a Non-Executive Director of Convatec Group Plc with effect from April 30, 2026 as he takes up his new appointment as Pro-Vice-Chancellor for Innovation at the University of Oxford. Since his appointment in September 2020, Professor Coussios has worked closely with the Board, senior management and Convatec's Chief Science, Innovation & Quality Officer Dr Divakar Ramakrishnan to transform and re-shape Convatec's research and development capabilities, accelerate new product development, and position the Company for sustained, innovation-led growth. Over the past six years, Convatec has completed several transformative strategic acquisitions, its internal new product development cycle time has been compressed by approximately 30%, and the vitality index has strengthened steadily from approximately 10% to approximately 30%, with 16 new product launches underway since 2022. The company confirms that the resolution to re-elect Professor Coussios as a Non-Executive Director of the company (resolution number 9) is now withdrawn.お知らせ • Mar 18Convatec Group PLC to Report First Half, 2026 Results on Aug 04, 2026Convatec Group PLC announced that they will report first half, 2026 results on Aug 04, 2026お知らせ • Mar 17Convatec and Eakin Healthcare Introduce Co-Branded Eakin Freeseal Ostomy Seal in North America Expanding the Esenta Family of AccessoriesConvatec, a medical products and technologies company focused on solutions for the management of chronic conditions, and Eakin Healthcare, a provider of ostomy solutions, announced the launch of eakin freeseal, the thinnest ostomy seal used to help prevent leaks and protect the skin around a stoma. This new co-branded seal is part of the ESENTA family of accessories, available in the United States. Ostomy seals are designed to create a protective layer around the stoma to prevent leakage. Recurrent leakage can lead to skin breakdown and irritation, leading to longer term issues, both physically and emotionally for patients. With approximately 1 million people living with a stoma in the United States, about 90% experience leakage at some point in their journey. The use of ostomy seals can reduce or eliminate leakage, leading to a better quality of life for those living with an ostomy. The eakin freeseal range includes two product lines, eakin freeseal air, and eakin freeseal versa, providing healthcare professionals with versatile options that combine discretion, comfort and high performance. While Convatec currently addresses the patient's needs with the eakin Cohesive seal, eakin freeseal provides healthcare professionals with a wider range of options to meet their clinical needs. The thinner offering, eakin freeseal air has a depth starting at 1.8mm, making it the thinnest seal on the market and is designed to be paired with convex pouches. Eakin freeseal versa is slightly thicker and designed to absorb fluid at the best rate in the market without breaking down, leading to easier removal for the end user. The thinness of this new ostomy seal, together with its composition and design, allows it to absorb up to four times its weight in fluid without breaking down underneath the skin barrier. This high performance, combined with eakin seals’ moldability, makes eakin freeseal a relatable solution to any person living with a stoma immediately post-surgery. Ostomy seals and barriers designed to prevent leakage and skin irritation is one of the largest product categories in the United States and continues to grow at a consistent rate. This co-branded product reflects Convatec and Eakin Healthcare’s ongoing commitment to patients and healthcare professionals to provide choice – working together to provide a better ostomy experience so patients can live the life they want. Integrating eakin seals into the ESENTA range reinforces the importance of using a reliable ostomy seal as part of the customers skincare routine.お知らせ • Feb 25Convatec Group PLC, Annual General Meeting, May 21, 2026Convatec Group PLC, Annual General Meeting, May 21, 2026.お知らせ • Feb 24Convatec Group PLC Recommends Final Dividend for the Year 2025, Payable on 28 May 2026Convatec Group PLC has recommended a final 2025 dividend of 5.367 cents per share, which would bring the full-year dividend to 7.244 cents per share (2024: 6.416 cents per share), an increase of 13% and a pay-out ratio when compared to adjusted net profit of 40% (2024: 42%). Ex-dividend is on 16 April 2026 with Record date on 17 April 2026. Payment date on 28 May 2026.お知らせ • Nov 13Convatec Group plc Maintains Revenue Guidance for the Year 2025ConvaTec Group PLC maintained revenue guidance for the year 2025. FY25 Group organic revenue growth excluding InnovaMatrix 6.0-6.5% (previously 5.5-7.0%). Medium-term targets: 5-7% organic revenue.お知らせ • Nov 08+ 2 more updatesConvaTec Group PLC Appoints Jonny Mason as Chief Executive Officer, Effective November 6, 2025ConvaTec Group PLC Board of Directors announced the appointment of Jonny Mason as Chief Executive Officer, effective November 6, 2025.Jonny Mason joined Convatec on 31 January 2022 as Chief Financial Officer and became a Director of the Company from 12 March 2022. He was appointed Interim CEO on 4 August 2025.お知らせ • Oct 28Convatec Group plc Announces Demise of Karim Bitar, Chief Executive OfficerConvaTec Group PLC announced that its Karim Bitar, who has been on medical leave of absence since 4 August 2025, has passed away. As previously announced, interim leadership arrangements remain in place and a further announcement will be made in due course.お知らせ • Aug 04+ 1 more updateConvaTec Group PLC Announces Change of Chief Executive OfficerConvatec announced that Chief Executive Officer Karim Bitar will be taking a medical leave of absence from the Company. During this period of absence, Jonny Mason, currently Chief Financial Officer, will become Interim Chief Executive Officer. Jonny and Fiona joined the Company in January 2022.お知らせ • Jul 31+ 1 more updateConvaTec Group PLC Provides Revenue Guidance for the Year 2025ConvaTec Group PLC provided revenue guidance for the year 2025. Group organic revenue growth excluding InnovaMatrix of 5.5%-7.0% (unchanged) driven by broadening product portfolio and focused commercial execution. InnovaMatrix® revenue of at least $75 million (unchanged).お知らせ • Jul 29ConvaTec Group PLC to Report Fiscal Year 2025 Results on Feb 25, 2026ConvaTec Group PLC announced that they will report fiscal year 2025 results on Feb 25, 2026お知らせ • Feb 27ConvaTec Group PLC, Annual General Meeting, May 22, 2025ConvaTec Group PLC, Annual General Meeting, May 22, 2025.お知らせ • Feb 26+ 1 more updateConvaTec Group PLC Recommends Final Dividend for the Year 2024, Payable on 29 May 2025The Board of ConvaTec Group PLC recommends a final dividend of 4.594 cents, resulting in a full year dividend of 6.416 cents, an increase of 3%. The final dividend proposed for 2024 is to be distributed on 29 May 2025 to shareholders on the register at the close of business on 22 April 2025 and is subject to shareholder approval at the Annual General Meeting on 22 May 2025. Ex-dividend 17 April 2025.お知らせ • Dec 17ConvaTec Group PLC to Report Fiscal Year 2024 Results on Feb 26, 2025ConvaTec Group PLC announced that they will report fiscal year 2024 results on Feb 26, 2025お知らせ • May 17ConvaTec Group PLC Provides Revenue Guidance for the Full Year 2024ConvaTec Group PLC provided revenue guidance for the full year 2024. Given the strong start so far this year, the company expects more balanced growth between first half and the second half of the year, and the company is on track to deliver its full year guidance of 5% to 7% organic revenue growth.お知らせ • Apr 16Convatec Launches New Esteem Body with Leak DefenseConvatec announced that it has launched Esteem Body™ with Leak Defense™ in the United States. The use of soft convexity ostomy barriers, starting post-surgery, is a growing practice fueled in part by global obesity, which has nearly tripled since 1975. The trend has driven abdominal topography changes and related challenges for ostomy care management, such as skin folds and complicated abdominal contours. Convatec's new offering to address this growing patient need is a comprehensive, one-piece, soft convexity ostomy system portfolio designed to fit a full range of body types and stoma shapes. The portfolio includes drainable, closed-end, and urostomy pouching solutions. There are five principal characteristics of convexity design, with two of these – 'tension location' and 'convex depth' - serving as significant drivers for achieving clinical goals of stoma protrusion and/or skin flattening. Convatec's Esteem Body™ offers eight different combinations of these key characteristics, with four 'tension locations' (split centrally and peripherally) across two different 'convex depths'. This range gives greater choice and provides the healthcare provider and ostomate the ability to achieve the best possible fit, given that each person living with an ostomy is unique. Leak Defense™ refers to the exclusive combination of Convatec's gold-standard adhesives (Durahesive® and Modified Stomahesive®) coupled with the comprehensive, soft convexity range, which together are designed to adapt to the body for a secure seal that can help prevent leaks and achieve a predictable wear time. The product also offers Convatec's new 'body' pouch, which comes in a patented '8-shape' that has been designed to sag less as it fills. The soft yet water-repellent 'flocking' material, that covers both sides of the pouch, is a warm gray color that hides content, even when wet, and is also discreet, even when worn under white clothing. The flocking was selected to optimise the functionality and discretion of Convatec's new, modern-looking and feeling pouch design. Convatec has recently published Finite Element Analysis (FEA) simulations that help visualize how both magnitude and location, of the tension applied to the ostomy and its surrounding multi-layer tissue, change in accordance with the product selected. It was clear how both tension location and convex depth are key contributors, working together with all convexity characteristics to achieve clinical stoma management goals. The FEA work is the foundation for the scientific and translational work Convatec is doing in ostomy care, and upon which research will be expanded to support clinicians and ostomates.お知らせ • Mar 08+ 1 more updateConvaTec Group plc Recommends Final Dividend, Payable on 23 May 2024ConvaTec Group PLC recommended final dividend of 4.460 cents resulting in full year dividend of 6.229 cents, an increase of 3%. The dividend will be payable on 23 May 2024 with Ex Dividend of 25 April 2024 and Record Date of 26 April 2024. The dividend is subject to shareholder approval at the Annual General Meeting on 16 May 2024.お知らせ • Mar 06ConvaTec Group PLC, Annual General Meeting, May 16, 2024ConvaTec Group PLC, Annual General Meeting, May 16, 2024. Agenda: To consider Final Dividend.お知らせ • Feb 16ConvaTec Group PLC to Report First Half, 2024 Results on Jul 30, 2024ConvaTec Group PLC announced that they will report first half, 2024 results on Jul 30, 2024お知らせ • Nov 14ConvaTec Group PLC Revises Earnings Guidance for the Year 2023ConvaTec Group PLC revised earnings guidance for the year 2023. For the year, the company now expect organic revenue growth for 2023 to be between 6.75% and 7.5% (previously 6.0%-7.5%).お知らせ • Sep 14ConvaTec Group PLC to Report Fiscal Year 2023 Results on Mar 06, 2024ConvaTec Group PLC announced that they will report fiscal year 2023 results on Mar 06, 2024お知らせ • Sep 08+ 1 more updateAn unknown buyer acquired an unknown minority stake in ConvaTec Group PLC from Novo Holdings A/S.An unknown buyer acquired an unknown minority stake in ConvaTec Group PLC from Novo Holdings A/S on September 8, 2023. Sten Scheibye will be stepping down from the Board. An unknown buyer completed the acquisition of an unknown minority stake in ConvaTec Group PLC from Novo Holdings A/S on September 8, 2023.お知らせ • Aug 04+ 1 more updateConvaTec Group plc Declares Interim Dividend for the Six Months Ended June 30, 2023ConvaTec Group PLC is declaring a 3% increase in the interim dividend to 1.769 cents per share (H1 2022: 1.717) reflecting continued confidence in the future performance of the Group and cash generation.お知らせ • May 19ConvaTec Group PLC Provides Revenue Guidance for the Year 2023ConvaTec Group PLC provided revenue guidance for the year 2023. For the year, the company now expects organic revenue growth to be between 5.0% and 6.5% (previously 4.5%-6.0%).お知らせ • Dec 14ConvaTec Group Plc to Report Fiscal Year 2022 Results on Mar 09, 2023ConvaTec Group Plc announced that they will report fiscal year 2022 results on Mar 09, 2023業績と収益の成長予測OTCPK:CNVV.F - アナリストの将来予測と過去の財務データ ( )USD Millions日付収益収益フリー・キャッシュフロー営業活動によるキャッシュ平均アナリスト数12/31/20282,9194244406101512/31/20272,7473633925491712/31/20262,5742772954921712/31/20252,439175285470N/A9/30/20252,397196312474N/A6/30/20252,356217337478N/A3/31/20252,322204306437N/A12/31/20242,289191275397N/A9/30/20242,245172266388N/A6/30/20242,200153257379N/A3/31/20242,171142248373N/A12/31/20232,142130238367N/A9/30/20232,113100166300N/A6/30/20232,0847093232N/A3/31/20232,07867115257N/A12/31/20222,07363138282N/A9/30/20222,07472155285N/A6/30/20222,07580173287N/A3/31/20222,05799192297N/A12/31/20212,038118212306N/A9/30/20212,016128247341N/A6/30/20211,994139282375N/A3/31/20211,944126298387N/A12/31/20201,894113313400N/A9/30/20201,87068305381N/A6/30/20201,84624296363N/A3/31/20201,83717318382N/A12/31/20191,82710340402N/A9/30/20191,81386N/A391N/A6/30/20191,800162N/A381N/A3/31/20191,816192N/A367N/A12/31/20181,832222N/A352N/A9/30/20181,843230N/A351N/A6/30/20181,855239N/A351N/A3/31/20181,810199N/A329N/A12/31/20171,765158N/A307N/A9/30/20171,72826N/A225N/A6/30/20171,691-106N/A143N/A3/31/20171,700-150N/A117N/A12/31/20161,688-203N/A75N/A9/30/20161,694-46N/A83N/A6/30/20161,677-15N/A128N/A3/31/20161,658-175N/A100N/A12/31/20151,650-93N/A100N/A9/30/20151,622-325N/A134N/A6/30/20151,662-315N/A165N/Aもっと見るアナリストによる今後の成長予測収入対貯蓄率: CNVV.Fの予測収益成長率 (年間19.8% ) は 貯蓄率 ( 3.5% ) を上回っています。収益対市場: CNVV.Fの収益 ( 19.8% ) はUS市場 ( 16.7% ) よりも速いペースで成長すると予測されています。高成長収益: CNVV.Fの収益は増加すると予測されていますが、大幅には増加しません。収益対市場: CNVV.Fの収益 ( 6.1% ) US市場 ( 11.7% ) よりも低い成長が予測されています。高い収益成長: CNVV.Fの収益 ( 6.1% ) 20%よりも低い成長が予測されています。一株当たり利益成長率予想将来の株主資本利益率将来のROE: CNVV.Fの 自己資本利益率 は、3年後には高くなると予測されています ( 24.4 %)成長企業の発掘7D1Y7D1Y7D1YHealthcare 業界の高成長企業。View Past Performance企業分析と財務データの現状データ最終更新日（UTC時間）企業分析2026/05/21 06:31終値2026/05/21 00:00収益2025/12/31年間収益2025/12/31データソース企業分析に使用したデータはS&P Global Market Intelligence LLC のものです。本レポートを作成するための分析モデルでは、以下のデータを使用しています。データは正規化されているため、ソースが利用可能になるまでに時間がかかる場合があります。パッケージデータタイムフレーム米国ソース例会社財務10年損益計算書キャッシュ・フロー計算書貸借対照表SECフォーム10-KSECフォーム10-Qアナリストのコンセンサス予想+プラス3年予想財務アナリストの目標株価アナリストリサーチレポートBlue Matrix市場価格30年株価配当、分割、措置ICEマーケットデータSECフォームS-1所有権10年トップ株主インサイダー取引SECフォーム4SECフォーム13Dマネジメント10年リーダーシップ・チーム取締役会SECフォーム10-KSECフォームDEF 14A主な進展10年会社からのお知らせSECフォーム8-K* 米国証券を対象とした例であり、非米国証券については、同等の規制書式および情報源を使用。特に断りのない限り、すべての財務データは1年ごとの期間に基づいていますが、四半期ごとに更新されます。これは、TTM（Trailing Twelve Month）またはLTM（Last Twelve Month）データとして知られています。詳細はこちら。分析モデルとスノーフレーク本レポートを生成するために使用した分析モデルの詳細は当社のGithubページでご覧いただけます。また、レポートの使用方法に関するガイドやYoutubeのチュートリアルも掲載しています。シンプリー・ウォールストリート分析モデルを設計・構築した世界トップクラスのチームについてご紹介します。業界およびセクターの指標私たちの業界とセクションの指標は、Simply Wall Stによって6時間ごとに計算されます。アナリスト筋Convatec Group PLC 17 これらのアナリストのうち、弊社レポートのインプットとして使用した売上高または利益の予想を提出したのは、 。アナリストの投稿は一日中更新されます。25 アナリスト機関Hassan Al-WakeelBarclaysSamuel EnglandBerenbergSusannah LudwigBernstein22 その他のアナリストを表示
お知らせ • Nov 13Convatec Group plc Maintains Revenue Guidance for the Year 2025ConvaTec Group PLC maintained revenue guidance for the year 2025. FY25 Group organic revenue growth excluding InnovaMatrix 6.0-6.5% (previously 5.5-7.0%). Medium-term targets: 5-7% organic revenue.
お知らせ • Jul 31+ 1 more updateConvaTec Group PLC Provides Revenue Guidance for the Year 2025ConvaTec Group PLC provided revenue guidance for the year 2025. Group organic revenue growth excluding InnovaMatrix of 5.5%-7.0% (unchanged) driven by broadening product portfolio and focused commercial execution. InnovaMatrix® revenue of at least $75 million (unchanged).
お知らせ • May 17ConvaTec Group PLC Provides Revenue Guidance for the Full Year 2024ConvaTec Group PLC provided revenue guidance for the full year 2024. Given the strong start so far this year, the company expects more balanced growth between first half and the second half of the year, and the company is on track to deliver its full year guidance of 5% to 7% organic revenue growth.
お知らせ • Nov 14ConvaTec Group PLC Revises Earnings Guidance for the Year 2023ConvaTec Group PLC revised earnings guidance for the year 2023. For the year, the company now expect organic revenue growth for 2023 to be between 6.75% and 7.5% (previously 6.0%-7.5%).
お知らせ • May 19ConvaTec Group PLC Provides Revenue Guidance for the Year 2023ConvaTec Group PLC provided revenue guidance for the year 2023. For the year, the company now expects organic revenue growth to be between 5.0% and 6.5% (previously 4.5%-6.0%).
お知らせ • May 06Convatec Showcases and Launches Advanced Wound Care Products and TechnologiesConvatec, a medical products and technology company focused on chronic condition management, took to the stage to showcase the breadth, depth and momentum behind its Advanced Wound Care innovation pipeline at the European Wound Management Association (EWMA) 2026 conference in Bremen, Germany, from 6–8 May 2026. Convatec’s Advanced Wound Care innovation is supported by compelling new data from randomised controlled trials (RCTs) and real-world studies, with 13 abstracts accepted for publication and presentation at EWMA evaluating outcomes in hard-to-heal wounds across foam, multimodal, nitric oxide-generating dressings, antimicrobial technology and Wound Hygiene. Convatec has launched or secured approvals for five new wound care products since 2022, including: ConvaFoam™: Best-in-class multi-layer foam dressing designed to be repositionable on application to avoid wasted dressing changes. ConvaFoam™ is the only foam dressing that combines three technologies – Aquacel® Hydrofiber®, superabsorber fibers and ConvaTac™ silicone – to deliver superior exudate management with skin friendly adhesion for longer lasting wear time. ConvaNiox™: A solution, shaping a new category in the management of hard-to-heal wounds by combining an advanced dressing technology with a powerful antimicrobial and antibiofilm agent, nitric oxide. ConvaNiox™’s multimodal technology, MultiFusion™, supports the healing of 60% more diabetic foot ulcers (DFUs), with 3x faster wound area reduction compared to standard-of-care dressings. Aquacel™ ConvaFiber™: Next-generation, soft, sterile and conformable primary dressing with advanced Hydrofiber® technology resulting in 45% more absorbency (vs Aquacel® Extra™), designed to manage a broad range of acute and chronic wounds. ConvaMatrix™: Recently approved innovative, single use wound matrix - a unique porcine placental-derived technology designed to support the body's natural healing response in DFUs and venous leg ulcers (VLUs). It combines the structural benefits of the placenta with the reproducibility and safety profile of a medical device. ConvaVAC™: First and only Negative Pressure Wound Therapy (NPWT) system partnered with Aquacel® Hydrofiber® technology utilising a bacterial sequestration and autolytic debridement wound contact layer to control the bioburden whilst delivering NPWT to promote wound healing. This year’s EWMA programme also marks 30 years of Hydrofiber® technology, Convatec’s proprietary wound care platform that underpins the next generation of wound care innovation to help manage the burden of wound care. Almost 1,500,000,000 Aquacel® dressings have been sold worldwide leveraging the technology over the last three decades. As part of the scientific programme at EWMA 2026, Convatec will host a series of symposia to explore emerging evidence from across its Advanced Wound Care portfolio and discuss what it means for real-world clinical practice, including: 6 May 2026 from 16:00 – 17:00: Introducing ConvaNiox™: multimodal, nitric oxide-generating dressing. The session, chaired by Professor José Luis Lázaro-Martínez, University of Madrid, will explore emerging laboratory and clinical evidence, highlighting ConvaNiox™’s multimodal approach to support healing in diabetic foot ulcers. 7 May 2026 from 16:16 – 17:15: A year of healing with ConvaFoam™: Advancing wound care with a next-generation foam dressing. The session will focus on the published clinical data exploring ConvaFoam™’s mode of action in pressure injury prevention, including insights on complex cases from guest speaker Dr Przemyslaw Lipinski, ARGO Medical Centre. Title Lead presenter Session information (CEST) Aquacel® Ag+ Extra™ Enhanced silver dressing versus dialkylcarbamoyl chloride-coated dressing in venous leg ulcers: a blinded re-assessment of randomized controlled trial findings Rebecca Rodger Wednesday 6 May 17:35 - 17:43 Room 4B Enhanced silver dressing improves slough and debridement in venous leg ulcers: post hoc analysis of a randomised controlled trial Rebecca Rodger Thursday 07 May 13:33 – 13:37 E-Poster Screen 4 ConvaNiox™ Assessing the speed of antimicrobial activity of a nitric oxide-generating dressing against antibiotic-resistant wound pathogens Tilly Coleborn Wednesday 6 May 12:17 - 12:21 E-Poster Screen 2 Assessing the sustained antimicrobial activity of a nitric oxide-generating dressing using antibiotic-resistant wound pathogens in a repeated inoculation model Tilly Coleborn Wednesday 6 May 12:21 - 12:25 E-Poster Screen 2 A multimodal dressing NO-generating: An Option for Both Acute and Chronic Wounds Dr. Francesca Pasquali Wednesday 6 May 12:29 - 12:33 CEST E-Poster Screen 2 Effectiveness of a nitric oxide-generating dressing in patients with diabetic foot ulcers: preliminary data from a case series study Dr. Marco Meloni Thursday 7 May 13:20 - 13:25 E-Poster Screen 3 To assess real-world characteristics and short-term outcomes of diabetic foot ulcers (DFUs) managed with a multi-modal nitric oxide-generating medical device using a structured clinical follow-up case report form Natalia Maella-Rius Thursday 7 May 13:30 - 13:35 E-Poster Screen 3 ConvaFoam™ Performance and user satisfaction with a superabsorbent dressing: results from an international survey Janet MacKenzie Thursday 7 May 12:54 – 12:57 E-Poster Screen 2 Early outcomes of implementing a new multilayer foam dressing in an acute setting: Assessing clinical and financial impact through value-based procurement Rebecca Rodger Thursday 7 May 16:10 - 16:15 E-Poster Screen 4 ConvaMatrix™ The clinical performance of decellularized porcine placental extracellular matrix (PPECM) in hard-to-heal wounds at a single-center: a retrospective study Helen Hahn Wednesday 6 May 00:00 - 00:00 E-poster browsing stations for display Real-world use of porcine placental extracellular matrix (PPECM) in hard-to-heal wounds: retrospective, multicenter analysis Helen Hahn Wednesday 6 May 00:00 - 00:00 E-poster browsing stations for display Real world data Hospital-to-home transition and care coordination in wound management: cost-effectiveness evaluation in a Brazilian specialized service Michele Rocha Thursday 7 May 10:36 - 10:39 E-Poster Screen 4 Therapeutic success indicators in hard-to-heal wounds: effectiveness of a specialized ambulatory care model Michele Rocha Thursday 7 May 16:30 - 16:35 E-Poster Screen 4.
お知らせ • Apr 13Convatec Group Plc Announces Professor Constantin Coussios OBE Steps Down as Non-Executive Director, Effective April 30, 2026Convatec Group Plc announces that Professor Constantin Coussios OBE will be stepping down as a Non-Executive Director of Convatec Group Plc with effect from April 30, 2026 as he takes up his new appointment as Pro-Vice-Chancellor for Innovation at the University of Oxford. Since his appointment in September 2020, Professor Coussios has worked closely with the Board, senior management and Convatec's Chief Science, Innovation & Quality Officer Dr Divakar Ramakrishnan to transform and re-shape Convatec's research and development capabilities, accelerate new product development, and position the Company for sustained, innovation-led growth. Over the past six years, Convatec has completed several transformative strategic acquisitions, its internal new product development cycle time has been compressed by approximately 30%, and the vitality index has strengthened steadily from approximately 10% to approximately 30%, with 16 new product launches underway since 2022. The company confirms that the resolution to re-elect Professor Coussios as a Non-Executive Director of the company (resolution number 9) is now withdrawn.
お知らせ • Mar 18Convatec Group PLC to Report First Half, 2026 Results on Aug 04, 2026Convatec Group PLC announced that they will report first half, 2026 results on Aug 04, 2026
お知らせ • Mar 17Convatec and Eakin Healthcare Introduce Co-Branded Eakin Freeseal Ostomy Seal in North America Expanding the Esenta Family of AccessoriesConvatec, a medical products and technologies company focused on solutions for the management of chronic conditions, and Eakin Healthcare, a provider of ostomy solutions, announced the launch of eakin freeseal, the thinnest ostomy seal used to help prevent leaks and protect the skin around a stoma. This new co-branded seal is part of the ESENTA family of accessories, available in the United States. Ostomy seals are designed to create a protective layer around the stoma to prevent leakage. Recurrent leakage can lead to skin breakdown and irritation, leading to longer term issues, both physically and emotionally for patients. With approximately 1 million people living with a stoma in the United States, about 90% experience leakage at some point in their journey. The use of ostomy seals can reduce or eliminate leakage, leading to a better quality of life for those living with an ostomy. The eakin freeseal range includes two product lines, eakin freeseal air, and eakin freeseal versa, providing healthcare professionals with versatile options that combine discretion, comfort and high performance. While Convatec currently addresses the patient's needs with the eakin Cohesive seal, eakin freeseal provides healthcare professionals with a wider range of options to meet their clinical needs. The thinner offering, eakin freeseal air has a depth starting at 1.8mm, making it the thinnest seal on the market and is designed to be paired with convex pouches. Eakin freeseal versa is slightly thicker and designed to absorb fluid at the best rate in the market without breaking down, leading to easier removal for the end user. The thinness of this new ostomy seal, together with its composition and design, allows it to absorb up to four times its weight in fluid without breaking down underneath the skin barrier. This high performance, combined with eakin seals’ moldability, makes eakin freeseal a relatable solution to any person living with a stoma immediately post-surgery. Ostomy seals and barriers designed to prevent leakage and skin irritation is one of the largest product categories in the United States and continues to grow at a consistent rate. This co-branded product reflects Convatec and Eakin Healthcare’s ongoing commitment to patients and healthcare professionals to provide choice – working together to provide a better ostomy experience so patients can live the life they want. Integrating eakin seals into the ESENTA range reinforces the importance of using a reliable ostomy seal as part of the customers skincare routine.
お知らせ • Feb 25Convatec Group PLC, Annual General Meeting, May 21, 2026Convatec Group PLC, Annual General Meeting, May 21, 2026.
お知らせ • Feb 24Convatec Group PLC Recommends Final Dividend for the Year 2025, Payable on 28 May 2026Convatec Group PLC has recommended a final 2025 dividend of 5.367 cents per share, which would bring the full-year dividend to 7.244 cents per share (2024: 6.416 cents per share), an increase of 13% and a pay-out ratio when compared to adjusted net profit of 40% (2024: 42%). Ex-dividend is on 16 April 2026 with Record date on 17 April 2026. Payment date on 28 May 2026.
お知らせ • Nov 13Convatec Group plc Maintains Revenue Guidance for the Year 2025ConvaTec Group PLC maintained revenue guidance for the year 2025. FY25 Group organic revenue growth excluding InnovaMatrix 6.0-6.5% (previously 5.5-7.0%). Medium-term targets: 5-7% organic revenue.
お知らせ • Nov 08+ 2 more updatesConvaTec Group PLC Appoints Jonny Mason as Chief Executive Officer, Effective November 6, 2025ConvaTec Group PLC Board of Directors announced the appointment of Jonny Mason as Chief Executive Officer, effective November 6, 2025.Jonny Mason joined Convatec on 31 January 2022 as Chief Financial Officer and became a Director of the Company from 12 March 2022. He was appointed Interim CEO on 4 August 2025.
お知らせ • Oct 28Convatec Group plc Announces Demise of Karim Bitar, Chief Executive OfficerConvaTec Group PLC announced that its Karim Bitar, who has been on medical leave of absence since 4 August 2025, has passed away. As previously announced, interim leadership arrangements remain in place and a further announcement will be made in due course.
お知らせ • Aug 04+ 1 more updateConvaTec Group PLC Announces Change of Chief Executive OfficerConvatec announced that Chief Executive Officer Karim Bitar will be taking a medical leave of absence from the Company. During this period of absence, Jonny Mason, currently Chief Financial Officer, will become Interim Chief Executive Officer. Jonny and Fiona joined the Company in January 2022.
お知らせ • Jul 31+ 1 more updateConvaTec Group PLC Provides Revenue Guidance for the Year 2025ConvaTec Group PLC provided revenue guidance for the year 2025. Group organic revenue growth excluding InnovaMatrix of 5.5%-7.0% (unchanged) driven by broadening product portfolio and focused commercial execution. InnovaMatrix® revenue of at least $75 million (unchanged).
お知らせ • Jul 29ConvaTec Group PLC to Report Fiscal Year 2025 Results on Feb 25, 2026ConvaTec Group PLC announced that they will report fiscal year 2025 results on Feb 25, 2026
お知らせ • Feb 27ConvaTec Group PLC, Annual General Meeting, May 22, 2025ConvaTec Group PLC, Annual General Meeting, May 22, 2025.
お知らせ • Feb 26+ 1 more updateConvaTec Group PLC Recommends Final Dividend for the Year 2024, Payable on 29 May 2025The Board of ConvaTec Group PLC recommends a final dividend of 4.594 cents, resulting in a full year dividend of 6.416 cents, an increase of 3%. The final dividend proposed for 2024 is to be distributed on 29 May 2025 to shareholders on the register at the close of business on 22 April 2025 and is subject to shareholder approval at the Annual General Meeting on 22 May 2025. Ex-dividend 17 April 2025.
お知らせ • Dec 17ConvaTec Group PLC to Report Fiscal Year 2024 Results on Feb 26, 2025ConvaTec Group PLC announced that they will report fiscal year 2024 results on Feb 26, 2025
お知らせ • May 17ConvaTec Group PLC Provides Revenue Guidance for the Full Year 2024ConvaTec Group PLC provided revenue guidance for the full year 2024. Given the strong start so far this year, the company expects more balanced growth between first half and the second half of the year, and the company is on track to deliver its full year guidance of 5% to 7% organic revenue growth.
お知らせ • Apr 16Convatec Launches New Esteem Body with Leak DefenseConvatec announced that it has launched Esteem Body™ with Leak Defense™ in the United States. The use of soft convexity ostomy barriers, starting post-surgery, is a growing practice fueled in part by global obesity, which has nearly tripled since 1975. The trend has driven abdominal topography changes and related challenges for ostomy care management, such as skin folds and complicated abdominal contours. Convatec's new offering to address this growing patient need is a comprehensive, one-piece, soft convexity ostomy system portfolio designed to fit a full range of body types and stoma shapes. The portfolio includes drainable, closed-end, and urostomy pouching solutions. There are five principal characteristics of convexity design, with two of these – 'tension location' and 'convex depth' - serving as significant drivers for achieving clinical goals of stoma protrusion and/or skin flattening. Convatec's Esteem Body™ offers eight different combinations of these key characteristics, with four 'tension locations' (split centrally and peripherally) across two different 'convex depths'. This range gives greater choice and provides the healthcare provider and ostomate the ability to achieve the best possible fit, given that each person living with an ostomy is unique. Leak Defense™ refers to the exclusive combination of Convatec's gold-standard adhesives (Durahesive® and Modified Stomahesive®) coupled with the comprehensive, soft convexity range, which together are designed to adapt to the body for a secure seal that can help prevent leaks and achieve a predictable wear time. The product also offers Convatec's new 'body' pouch, which comes in a patented '8-shape' that has been designed to sag less as it fills. The soft yet water-repellent 'flocking' material, that covers both sides of the pouch, is a warm gray color that hides content, even when wet, and is also discreet, even when worn under white clothing. The flocking was selected to optimise the functionality and discretion of Convatec's new, modern-looking and feeling pouch design. Convatec has recently published Finite Element Analysis (FEA) simulations that help visualize how both magnitude and location, of the tension applied to the ostomy and its surrounding multi-layer tissue, change in accordance with the product selected. It was clear how both tension location and convex depth are key contributors, working together with all convexity characteristics to achieve clinical stoma management goals. The FEA work is the foundation for the scientific and translational work Convatec is doing in ostomy care, and upon which research will be expanded to support clinicians and ostomates.
お知らせ • Mar 08+ 1 more updateConvaTec Group plc Recommends Final Dividend, Payable on 23 May 2024ConvaTec Group PLC recommended final dividend of 4.460 cents resulting in full year dividend of 6.229 cents, an increase of 3%. The dividend will be payable on 23 May 2024 with Ex Dividend of 25 April 2024 and Record Date of 26 April 2024. The dividend is subject to shareholder approval at the Annual General Meeting on 16 May 2024.
お知らせ • Mar 06ConvaTec Group PLC, Annual General Meeting, May 16, 2024ConvaTec Group PLC, Annual General Meeting, May 16, 2024. Agenda: To consider Final Dividend.
お知らせ • Feb 16ConvaTec Group PLC to Report First Half, 2024 Results on Jul 30, 2024ConvaTec Group PLC announced that they will report first half, 2024 results on Jul 30, 2024
お知らせ • Nov 14ConvaTec Group PLC Revises Earnings Guidance for the Year 2023ConvaTec Group PLC revised earnings guidance for the year 2023. For the year, the company now expect organic revenue growth for 2023 to be between 6.75% and 7.5% (previously 6.0%-7.5%).
お知らせ • Sep 14ConvaTec Group PLC to Report Fiscal Year 2023 Results on Mar 06, 2024ConvaTec Group PLC announced that they will report fiscal year 2023 results on Mar 06, 2024
お知らせ • Sep 08+ 1 more updateAn unknown buyer acquired an unknown minority stake in ConvaTec Group PLC from Novo Holdings A/S.An unknown buyer acquired an unknown minority stake in ConvaTec Group PLC from Novo Holdings A/S on September 8, 2023. Sten Scheibye will be stepping down from the Board. An unknown buyer completed the acquisition of an unknown minority stake in ConvaTec Group PLC from Novo Holdings A/S on September 8, 2023.
お知らせ • Aug 04+ 1 more updateConvaTec Group plc Declares Interim Dividend for the Six Months Ended June 30, 2023ConvaTec Group PLC is declaring a 3% increase in the interim dividend to 1.769 cents per share (H1 2022: 1.717) reflecting continued confidence in the future performance of the Group and cash generation.
お知らせ • May 19ConvaTec Group PLC Provides Revenue Guidance for the Year 2023ConvaTec Group PLC provided revenue guidance for the year 2023. For the year, the company now expects organic revenue growth to be between 5.0% and 6.5% (previously 4.5%-6.0%).
お知らせ • Dec 14ConvaTec Group Plc to Report Fiscal Year 2022 Results on Mar 09, 2023ConvaTec Group Plc announced that they will report fiscal year 2022 results on Mar 09, 2023